Results 61 to 70 of about 755,388 (347)

The zinc finger domains of PARP‐1 are selectively and potently inhibited by the Au(I)‐based drugs sodium aurothiomalate and aurothioglucose

FEBS Letters, EarlyView.
PARP‐1 is a key enzyme in the DNA damage response, and its inhibition induces cancer cell death via synthetic lethality. Au(I)‐based drugs, such as aurothioglucose and sodium aurothiomalate, block PARP‐1's DNA‐dependent activity by targeting its zinc finger domains.
Uliana Bashtanova, Melinda Jane Duer
wiley   +1 more source

Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level

Journal of Hematology & Oncology, 2016
Background The poor prognosis and the limited efficacy of targeted therapy in patients with triple-negative breast cancer (TNBC) have raised the need for alternative therapies.
De-Gang Song, Qunrui Ye, Mathilde Poussin, Jessica A. Chacon, Mariangela Figini, Daniel J. Powell   +5 more
doaj   +1 more source

Paraneoplastic thrombocytosis in ovarian cancer [PDF]

, 2012
<p>Background: The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the role that platelets play in abetting cancer growth are unclear.</p> <p>Methods: We analyzed clinical data on 619 patients with epithelial ...
Akl EA, Alpa M. Nick, Angela F. Drew, Anil K. Sood, Bulent Ozpolat, Chad V. Pecot, Charles N. Landen, Diana Urbauer, Donald Lamkin, Edward H. Ahn, Erin R. King, Frances Balkwill, Francisca Gushiken, Gabriel Lopez-Berestein, Guillermo N. Armaiz-Pena, Hannah Gershenson, Hee Dong Han, Hernan G. Vasquez, Iain A. McNeish, Ibrahim Tekedereli, Jermaine Coward, Justin Bottsford-Miller, Katherine Collins, Koen DeGeest, Koji Matsuo, Mian M.K. Shahzad, Michael T. Deavers, Rajesha Rupaimoole, Rebecca L. Stone, Riess L, Rui Wang, Susan K. Lutgendorf, Vahid Afshar-Kharghan, Virginia K. Bond, Wah Chiu, Wei Hu   +35 more
core   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Advancing Research Alongside Patient Partners: Next-Generation Best Practices for Effective Collaboration in Health Research

Current Oncology
Ovarian Cancer Canada’s Patient Partners in Research (PPiR) is a national volunteer-based program that trains and connects individuals with lived ovarian cancer (OC) experience to diverse research opportunities, to maximize the clinical relevance and ...
Ally C. Farrell, Jessica A. Lawson, Ovarian Cancer Canada’s Patient Partners in Research Team, Alison Ross, Alicia A. Tone   +4 more
doaj   +1 more source

Can 9q34.2 rs633862 polymorphism predict survival in epithelial ovarian cancer? [PDF]

PeerJ, 2017
Objective Our previous genome-wide association study (GWAS) identified that the ABO rs633862 variant in chromosome 9q34.2 was associated with the risk of epithelial ovarian cancer (EOC) in Chinese Han women.
Rong Jiang, Yuan Xu, Pan Wang, Xi Cheng, Tingyan Shi, Rongyu Zang   +5 more
doaj   +2 more sources

Inflammation is a key contributor to ovarian cancer cell seeding. [PDF]

, 2018
The incidence of ovarian cancer dramatically increases in early menopause but the factors contributing to cancer onset are unclear. Most ovarian cancers originate in the fallopian tube with subsequent implantation of malignant cells into the ovary ...
Jia, Dongyu, Katsumata, Makoto, Nagaoka, Yoshiko, Orsulic, Sandra   +3 more
core   +1 more source

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer [PDF]

, 2017
SRC tyrosine kinase is frequently overexpressed and activated in late-stage, poor prognosis ovarian tumours, and preclinical studies have supported the use of targeted SRC inhibitors in the treatment of this disease.
El-Helali, Aya, Kennedy, Richard D., McCabe, Nuala, McGivern, Niamh, Mcneish, Iain A., Mullan, Paul, Paul Harkin, D   +6 more
core   +2 more sources

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Transcriptomic Analyses of Ovarian Clear Cell Carcinoma Spheroids Reveal Distinct Proliferative Phenotypes and Therapeutic Vulnerabilities

Cells
Cancer cell spheroids autonomously form in the ascites fluid and are considered a conduit for epithelial ovarian cancer metastasis within the peritoneal cavity. Spheroids are homotypic, avascular 3D structures that acquire resistance to anoikis to remain
Bart Kolendowski, Sylvia Cheng, Yudith Ramos Valdes, Trevor G. Shepherd, Gabriel E. DiMattia   +4 more
doaj   +1 more source